WARNING: CONGESTIVE HEART FAILURE
Thiazolidinediones, including ACTOS, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions].
After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered.
ACTOS is not recommended in patients with symptomatic heart failure.
Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications and Warnings and Precautions].
ACTOS tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone.
Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo. No differences were found in the pharmacologic activity between the two enantiomers.
Monotherapy and Combination Therapy
ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies].
Important Limitations of Use
ACTOS exerts its antihyperglycemic effect only in the presence of endogenous insulin. ACTOS should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.
Use caution in patients with liver disease [see Warnings and Precautions].
Media Articles Related to Actos (Pioglitazone)
Study Refutes Notion That Diabetes Drug Actos Raises Bladder Cancer Risk
Source: MedicineNet Bladder Cancer Specialty [2015.07.22]
Title: Study Refutes Notion That Diabetes Drug Actos Raises Bladder Cancer Risk
Category: Health News
Created: 7/21/2015 12:00:00 AM
Last Editorial Review: 7/22/2015 12:00:00 AM
Source: MedicineNet Lactose Intolerance Specialty [2015.06.30]
Title: Lactose Intolerance
Category: Symptoms and Signs
Created: 6/30/2015 12:00:00 AM
Last Editorial Review: 6/30/2015 12:00:00 AM
Lactose Tolerance Test
Source: MedicineNet Stool Acidity Test Specialty [2014.03.04]
Title: Lactose Tolerance Test
Category: Procedures and Tests
Created: 11/27/1998 12:00:00 AM
Last Editorial Review: 3/4/2014 12:00:00 AM
ACTOS shows significant benefits for diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
A study shows that ACTOS reduces the risk of cardiovascular events by an extra 16% on top of standard medication.
Published Studies Related to Actos (Pioglitazone)
Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection. 
Background Chronic hepatitis C infection frequently coexists with human
immunodeficiency virus (HIV) and together are associated with increased hepatic
steatosis... This small study shows that pioglitazone
helps ameliorate steatosis in the context of HIV/HCV co-infection.
Effects of pioglitazone on bone in postmenopausal women with impaired fasting
glucose or impaired glucose tolerance: a randomized, double-blind,
placebo-controlled study. 
on bone mineral density (BMD) and turnover... CONCLUSIONS: Maximal-dose pioglitazone had no effects on BMD or bone turnover,
Clinical efficacy of pioglitazone: generic vs. original product. 
CONCLUSION: These findings indicated that both formulations were bioequivalent as
Pioglitazone-mediated changes in lipoprotein particle composition are predicted
by changes in adiponectin level in type 2 diabetes. 
factors after an intervention that alters adiponectin levels... CONCLUSION: Increased adiponectin contributed to treatment-related benefit in
Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. [2011.11]
CONCLUSIONS: Results from clinical trials and current safety data suggest that rosiglitazone should not be used for the treatment of AD. Application of results from trials evaluating pioglitazone in the treatment of AD is limited because of major trial limitations; therefore, it should not be recommended at this time. Although these drugs are not commonly used in the treatment of AD, further pharmacoepidemiologic studies are warranted before their use can be recommended.
Clinical Trials Related to Actos (Pioglitazone)
Effects of Pioglitazone on Platelet Function [Active, not recruiting]
The purpose of this study is to determine how pioglitazone and aspirin affect platelets in
the blood of diabetic and non-diabetic subjects. Platelets are small cells in the blood
that help with blood clotting. Pioglitazone is a drug that is used to lower blood sugar and
fats by helping the body to use insulin correctly. Pioglitazone is presently used to treat
diabetes but has not been approved for non-diabetics. This study will determine whether
pioglitazone reduces the activity of platelets in people who are or are not also taking
Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function [Completed]
Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin
sensitivity in skeletal muscle, liver, and fat cells. Despite the beneficial effects of
pioglitazone to improve insulin sensitivity and reduce cardiovascular disease in high risk
type 2 diabetic patients, weight gain has been a limiting factor. Exenatide, another
agent used for treatment of T2DM, improves glycemic control and promotes moderate weight
loss. In this proposal we will examine the effect of combination therapy with pioglitazone
plus exenatide on body weight, fat topography, beta cell function, glycemic control, and
plasma lipid levels in subjects with type 2 diabetes mellitus compared to treatment with
each drug separately. Assessment of beta cell function will be performed by measuring the
maximal insulin secretory capacity using a maximal hyperglycemic stimulus combined with an
intravenous arginine stimulus.
Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants [Completed]
Renal and Hormonal Effects of Pioglitazone [Completed]
The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle [Completed]
Subjects with type 2 diabetes will be treated with Actos or placebo for eight weeks and
needle biopsies of muscle will quantify changes in any of seven different glucose transport
proteins in muscle.
Reports of Suspected Actos (Pioglitazone) Side Effects
Bladder Cancer (1096),
Bladder Transitional Cell Carcinoma (104),
Weight Increased (36),
Blood Glucose Increased (34),
Myocardial Infarction (33),
Bladder Neoplasm (27),
Cardiac Failure Congestive (26),
Prostate Cancer (26), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Actos has an overall score of 7. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Actos review by 65 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || diabetes|
|Dosage & duration:|| || 15 mg. taken one a day for the period of I have been taking it for 5 years|
|Other conditions:|| || NONE|
|Other drugs taken:|| || NONE|
|Benefits:|| || THE TREATMENT BENEFIT IS TO CONTROL THE GLUCOSE IN MY BLOOD, ALONG WITH A HEALTHY DIET AND AVOID SWEETS AND STARCHES.|
|Side effects:|| || NO SIDE EFFECTS SO FAR, BUT ALL PRESCRIPTION DRUGS HAVE SOME EFFECTS WITH THE YEARS. THAT'S WHY I TRY TO STAY AWAY FROM DRUGS.|
|Comments:|| || I TAKE ONE ACTOS 15 MG IN THE MORNING. HAVE BLOOD TESTS DONE EVERY 3 MONTHS TO CHECK MY KIDNEYS, GLUCOSE LEVEL, CHILESTEROL, ETC. ALSO HAVE MY EYES CHECK EVERY 12 MONTHS, AND MY FEET AS WELL.|
Page last updated: 2015-08-10